| P2093 | author name string | C Assaf | |
| | J P Nicolay | |
| P2860 | cites work | Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions | Q28306039 |
| | European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. | Q30235003 |
| | Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. | Q33987080 |
| | Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment | Q34633209 |
| | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study | Q36043066 |
| | Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type | Q36459144 |
| | Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion | Q36553825 |
| | Optimal combination with PUVA: rationale and clinical trial update. | Q36808918 |
| | Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? | Q36913972 |
| | The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Q36920426 |
| | Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model | Q37163606 |
| | Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases | Q37201934 |
| | Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB. | Q37262461 |
| | Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers | Q38179568 |
| | Updating ECP action mechanisms | Q38212474 |
| | Sézary syndrome: old enigmas, new targets | Q38772711 |
| | The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines. | Q38784200 |
| | Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target. | Q38890130 |
| | IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. | Q38943442 |
| | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial | Q39363280 |
| | Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. | Q39701541 |
| | New Targeted Treatments for Cutaneous T-cell Lymphomas | Q40255151 |
| | UVB in the management of early stage mycosis fungoides | Q40326881 |
| | Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. | Q40473507 |
| | Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. | Q40602894 |
| | A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides | Q40768413 |
| | Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients | Q40970585 |
| | NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib | Q41233629 |
| | Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. | Q42232495 |
| | Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa | Q42471736 |
| | Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up | Q42480934 |
| | Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. | Q43249154 |
| | Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results | Q43594172 |
| | Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides | Q43797354 |
| | Bexarotene therapy for mycosis fungoides and Sézary syndrome. | Q46119707 |
| | Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. | Q46395734 |
| | Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome | Q46535550 |
| | Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients | Q46744850 |
| | Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. | Q50477276 |
| | A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. | Q51484852 |
| | Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. | Q53122623 |
| | [Update on extracorporeal photopheresis]. | Q53323672 |
| | Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. | Q53517013 |
| | Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. | Q53548352 |
| | Oral methoxsalen photochemotherapy of mycosis fungoides | Q67527216 |
| | Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis | Q67570530 |
| | Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma | Q68200314 |
| | Interferon alfa-2a in the treatment of cutaneous T cell lymphoma | Q69735852 |
| | Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma | Q73867868 |
| | Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II | Q77531747 |
| | Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma | Q81793195 |
| | Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas | Q82383994 |
| | Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome | Q83018744 |
| | PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series | Q84498470 |
| | Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy | Q85841955 |
| | Brief S2k guidelines--Cutaneous lymphomas | Q86895371 |
| | Localized conventional radiotherapy in the treatment of Mycosis Fungoides: our experience in 100 patients | Q87348496 |
| | [Management of cutaneous lymphomas] | Q88026912 |
| P433 | issue | 9 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | mycosis fungoides | Q1891209 |
| P304 | page(s) | 702-710 | |
| P577 | publication date | 2017-09-01 | |
| P1433 | published in | Die Dermatologie | Q15756740 |
| P1476 | title | [Treatment of mycosis fungoides and Sézary syndrome]. | |
| P478 | volume | 68 | |